Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Companyâs proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Companyâs segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļPGEN
āļāļ·āđāļāļāļĢāļīāļĐāļąāļPrecigen Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļAug 08, 2013
āļāļĩāļāļĩāđāļSabzevari (Helen)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ143
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļAug 08
āļāļĩāđāļāļĒāļđāđ20374 Seneca Meadows Parkway
āđāļĄāļ·āļāļGERMANTOWN
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ20876
āđāļāļĢāļĻāļąāļāļāđ13015569900
āđāļ§āđāļāđāļāļāđhttps://precigen.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļPGEN
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļAug 08, 2013
āļāļĩāļāļĩāđāļSabzevari (Helen)
Dr. Helen Sabzevari, Ph.D.
Dr. Helen Sabzevari, Ph.D.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
Mr. Fred Hassan
Independent Director
Mr. Steven R. Frank
Independent Director
Mr. James S. (Jim) Turley
Mr. James S. (Jim) Turley
Lead Independent Director
Lead Independent Director
Ms. Vinita D. Gupta
Independent Director
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Independent Director
Ms. Nancy Howell Agee
Independent Director
Mr. Phil Tennant
Chief Commercial Officer
Mr. Cesar L. Alvarez
Independent Director
Mr. Donald P. Lehr
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Dr. Helen Sabzevari, Ph.D.
Dr. Helen Sabzevari, Ph.D.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
Mr. Fred Hassan
Independent Director
Mr. Steven R. Frank
Independent Director
Mr. James S. (Jim) Turley
Mr. James S. (Jim) Turley
Lead Independent Director
Lead Independent Director
Ms. Vinita D. Gupta
Independent Director
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Independent Director
Inspire Small/Mid Cap ESG ETF
ProShares Ultra Nasdaq Biotechnology
Invesco Nasdaq Biotechnology ETF
State Street SPDR S&P Biotech ETF
Vanguard US Momentum Factor ETF
Direxion Daily S&P Biotech Bull 3X Shares
iShares Biotechnology ETF
iShares Russell 2000 Growth ETF
ProShares UltraPro Russell2000
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Inspire Small/Mid Cap ESG ETF
āļŠāļąāļāļŠāđāļ§āļ0.24%
ProShares Ultra Nasdaq Biotechnology
āļŠāļąāļāļŠāđāļ§āļ0.14%
iShares Micro-Cap ETF
āļŠāļąāļāļŠāđāļ§āļ0.12%
Invesco Nasdaq Biotechnology ETF
āļŠāļąāļāļŠāđāļ§āļ0.12%
State Street SPDR S&P Biotech ETF
āļŠāļąāļāļŠāđāļ§āļ0.11%
Vanguard US Momentum Factor ETF
āļŠāļąāļāļŠāđāļ§āļ0.1%
Direxion Daily S&P Biotech Bull 3X Shares
āļŠāļąāļāļŠāđāļ§āļ0.06%
iShares Biotechnology ETF
āļŠāļąāļāļŠāđāļ§āļ0.05%
iShares Russell 2000 Growth ETF
āļŠāļąāļāļŠāđāļ§āļ0.03%
ProShares UltraPro Russell2000
āļŠāļąāļāļŠāđāļ§āļ0.02%
āļĄāļĩāļāļēāļĢāļāđāļēāļĒāđāļāļīāļāļāļąāļāļāļĨāđāļāđāļāļāļģāļāļ§āļāļĢāļ§āļĄ
0.00
USD āđāļāļāđāļ§āļ 5 āļāļĩāļāļĩāđāļāđāļēāļāļĄāļē

āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ